Healthcare-associated Exposure to Neisseria meningitidis (N. meningitidis)

N. meningitidis is transmitted from person-to-person by direct contact with respiratory secretions and saliva and by inhalation of airborne droplets generated by coughing or sneezing. At risk HCP (e.g., asplenia or persistent complement component deficiencies) should receive a 2-dose series of the Men ACWY vaccine, because these conditions increase the risk for meningococcal disease.²⁰ All HCP with close or lengthy contact with a patient with meningococcal disease are considered at increased risk of infection and should receive antimicrobial PEP within 24 hours of exposure.²¹